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Abstract
Tacrolimus (FK506) is the most widely used anti-rejection drug in kidney transplantation, especially its extended release Tacrolimus formulation 
(ER-Tac, Advagraf), which is used when target blood levels can be difficult to reach in high metabolizer patients. In this retrospective monocen-
tric study, we analyzed the effect of a switch from ER-Tac to LifeCycle Pharma Tacrolimus (LPCT, Envarsus) on the dose/level ratio of FK506 
in high metabolizer patients that cannot achieve target blood levels in the first 6 months after transplantation.
We observed a statistically significant improvement in the level to dose ratio after the switch. Renal function remained stable. We also observed 
a reduction in the development of tremors.
Our data suggest that LPCT can be used in a safer way in high metabolizer kidney transplant recipients.
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Introduction
Tacrolimus (FK506) is the most widely used immunosup-
pressive drug in kidney transplant patients for preventing 
graft rejection. However, it has a narrow therapeutic range 
and requires close monitoring. In fact, blood concentration 
below the therapeutic range is associated with increased risk 
of rejection, whereas blood concentration over the ther-
apeutic range increases the risk of toxicity and side effects 
(anticalcineurinc nephrotoxicity, infections, diabetes, BK 
virus nephropathy, tremor). Various formulations of FK506 
are currently available: immediate-release Tacrolimus formu-
lations (IR-Tac), extended-release tacrolimus formulations 
(ER-Tac), and LifeCycle Pharma Tacrolimus (LCPT). Twice-
daily IR-Tac (Prograf®, Astellas Pharma, or the generic 
formulation) was the first produced formulation, and it is 
administered every 12 h. The second produced formulation 
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Methods
We selected 10 patients who received kidney transplantation 
in our institution and were switched from ER-Tac to LCPT 
in the first 6 months after transplantation because of diffi-
culty in reaching target tacrolimus blood levels (8–12 ng/mL 
in the first 6 months after surgery) in spite of a continuous 
increase in oral daily dose of Tacrolimus. The treatment 
switch was decided by the nephrologists in charge of the 
patients. The dose of LPCT was calculated as the 70% of 
the the dose of ER-TAC at the time of the switch, as recom-
mended by the manufacter.
In this analysis, we compared FK 506 blood levels, serum 
creatinine, dose to level ratio, glycemia, ER-Tac, and LCPT 
doses at time of switch, after 1 week, and after 1 month. 
Morevorer, we wanted to observe whether an improvement 
or a disappearance of tremors occurred after the treat-
ment switch. Statistical analysis included Student t-test for 
unpaired groups. Statistical analysis was performed using 
SPSS® software.
was ER-Tac (Advagraf®, Astellas Pharma), and it allowed 
once-daily administration. A new, once-daily ER-Tac (LCPT: 
Envarsus®, Chiesi Farmaceutici) was released recently. It 
was designed with a Melt-Dose technology, with the aim to 
increase the bioavailability of the drug with low water sol-
ubility. LCPT releases the drug in a controlled manner at a 
predetermined rate, duration, and location in the gastrointes-
tinal tract to achieve and maintain a more stable therapeutic 
blood concentration of FK506 (1). Patients with FK506’s 
administered dose and level ratio > 1 are defined as high 
metabolizers. In these patients, achieving target blood levels 
of immunosuppressants can be particularly difficult, and it 
represents a recurring challenge for physicians. This is par-
ticularly important in the first months after transplantation 
when the risk of acute rejection is higher. The aim of our ret-
rospective observational study was to analyze the effects of 
a switch from ER-Tac to LCPT on bllod tacrolimus trhough 
levels and on dose to level ratio in high metabolizer kidney 
transplant recipients who did not achieve optimal blood lev-
els of tacrolimus.
Table 1. In the left colon parameters are presented  at the time of the switch (t0) and after 1 month (t1)
 Media ± SD HR (95% CI) P
Inferior Superior T
Creatinine T0 (mg/dL) 2.10 ± 1.44 −0.28 1.24 1.44 0.188
Creatinine T1 (mg/dL) 1.62 ± 0.57
Azotemia T0 (mg/dL) 0.75 ± 0.69 −0.29 0.62 0.83 0.427
Azotemia T1 (mg/dL) 0.58 ± 0.27
Proteinuria T0 (gr/24h) 0.56 ± 0.55 0.11 0.34 4.75 0.001
Proteinuria T1 (gr/24h) 0.33 ± 0.55
Glycemia T0 (mg/dL) 90.89 ± 8.89 −16.21 1.54 −1.90 0.093
Glycemia T1 (mg/dL) 98.22 ± 15.50
Cholesterol T0 (mg/dL) 202.63 ± 59.13 −18.25 25.75 0.40 0.69
Cholesterol T1 (mg/dL) 198.88 ± 47.05
 Fk levels T0 (ng/mL) 9.82 ± 3.39 −2.38 1.45 −0.56 0.59
Fk levels T1 (ng/mL) 10.28 ± 3.79
Fk dose T0 (mg/day) 16.44 ± 5.38 2.36 8.46 4.09 0.003
Fk dose T1 (mg/day) 11.02 ± 6.20
Fk dose/level T0 2.94 ± 1.16 1.09 2.36 6.27 0.0001
Fk dose/level T1 1.21 ± 0.84
In the P value colomn statistically significant values are expressed in bold character.
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higher peak concentrations, potentially magnifying the risk 
for toxicity and adverse outcomes. This pharmacogenetic 
effect was attenuated by delayed tacrolimus absorption with 
LCPT (6). In addition, in our case study, we observed a sim-
ilar rate of renal function and an improvement in the devel-
opment of tremors after a switch from ER-TAC to LCPT. 
Tremor is a common tacrolimus treatment side effect, and 
it is correlated with peak-dose drug concentration. LCPT 
formulations have a reduced maximum blood concentra-
tion (Cmax) with comparable AUC exposure. All patients 
enrolled in our study reported an improvement in tremor 
after the switch. Langone et al. enrolled 38 kidney transplant 
recipients with a reported clinically significant tremor and 
switched them to LCPT. A statistically and clinically signifi-
cant improvement in tremor resulted after the pharmacolog-
ical conversion (7). Finally, we can also observe a reduction 
in costs due to the fact that target blood levels were achieved 
with a lower drug dose.
It is necessary to point out some limitations of our study; 
in particular, we underline that this is a retrospective mono-
centric small study, and the patient selection was not per-
formed following a protocol but was decided by physicians 
on their clinical interpretation. In spite of the shortcomings, 
our data suggest that LCPT can be used in a safer way in 
high metabolizer kidney transplant recipients.
Conclusions
LCPT formulations have demonstrated noninferiority, 
similar safety, improved bioavailability, a consistent con-
centration time profile, and less peak and peak-trough fluc-
tuations compared to other formulations. Also, our data 
express a better FK506 dose to level ratio and a reduction 
of  tremors after the switch to LCPT. Further randomized 
studies on larger populations are needed to confirm the 
effective advantages of  the switch from IR-Tac and ER-Tac 
to LCPT.
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